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TO THE EDITOR
Behc¸et’s disease (BD) is a chronic,
relapsing, systemic vasculitis of un-
known etiology. Patients with BD ex-
hibit elevated levels of proinflammatory
cytokines and the affected organs show
a significant neutrophile and lympho-
cyte infiltration. Current evidence sug-
gest that the activated lymphocytes
contribute to neutrophile and endothe-
lial cell activation in these patients
(Akman et al., 2007; Alpsoy et al.,
2007). Recently, a new subset of Th
cells, Th17 cells, in part characterized
by their production of IL-17 has been
identified and their roles in inflamma-
tion or immune regulation are under
intensive investigation. IL-17 promotes
inflammation by inducing various
proinflammatory cytokines and chemo-
kines; it modulates the secretion of IL-1,
tumor necrosis factor-a, IL-6, IL-8, and
prostaglandin E2. IL-17 also increases
CXC chemokine secretion. Therefore,
IL-17 causes neutrophil influx and
regulates neutrophil-mediated inflam-
matory responses. Th17 cells have the
most remarkable effects on neutrophil
activity within T-cell sub-populations
(Furuzawa-Carballeda et al., 2007). It is
well known that neutrophil activity is
increased in BD. Again, IL-6, IL-1, and
tumor necrosis factor-a, which have a
role in the differentiation of naive T
cells to Th17 cells, are found
to be elevated in patients with BD
(Fossiez et al., 1996; Akman et al.,
2006). Serum G-CSF level was also
reported significantly higher in active
patients than in those inactive patients
with BD (Kawakami et al., 2004).
In a recent study, Chi et al. (2008)
have shown elevated production of
IL-17, IL-23, and IFN-g by peripheral
blood mononuclear cells (PBMC) be-
sides increased frequencies of IL-17 and
IFN-g-producing T cells in BD patients
with active uveitis. In this study, we
particularly aimed at investigating
the role of IL-17A in the activity and
different organ involvements of the
disease.
Forty-five patients (24 women,
21 men; mean age, 40 years) with BD,
diagnosed according to the criteria of
the International Study Group for BD
(1990), and 33 age- and sex-matched
healthy volunteers (17 women, 16 men;
mean age, 36 years) were enrolled in
the study. The study was approved
by the Ethics Committee of Akdeniz
University (Institutional approval num-
ber: 2007.02.0122007). Informed con-
sent was obtained from all participants,
and study was conducted according to
the Declaration of Helsinki Principles.
Control group had neither family
history nor symptoms related to BD.
Twenty-two patients (10 women,
12 men, mean age 41) with BD were
at inactive stage, whereas 23 of them
(14 women, 9 men, mean age 39 years)
were at active stage. Any patient having
any active sign of the disease at the time
of blood drawn was accepted at active
stage. All patients had oral ulcers, and
in 16 of them this finding was at active
stage. The same figure was 16 and 2
for genital ulcers, 13 and 1 for erythema
nodosum, 23 and 6 for articular
involvement, 18 and 8 for ocular
symptoms. In addition, six patients
had vascular, and two gastrointestinal
involvement.
We examined serum levels of IL-17A
by ELISA. In vitro IL-17A response of
PBMC of patients with BD and controls
after stimulation with Streptococcus
sanguis (S. sanguis), Escherichia coli
(E. coli), and phytohemaglutinin
were evaulated by enzyme-linked
immunosorbent spot method. The
proportion of IL-17A-secreting cells
(Th17 cells) in nine patients with active
organ involvement and nine healthyAbbreviations: BD, Behc¸et’s disease; PBMC, peripheral blood mononuclear cells
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volunteers was detected by flow cyto-
metry with intracellular cytokine stain-
ing method.
Serum IL-17A levels of BD patients
(20.7±12.9) were significantly higher
than healthy controls (11.8±3.4)
(P¼0.011). Active BD patients (28.7±
12.8) showed significantly higher
levels of IL-17A compared with inactive
patients (11.9±2.7) and healthy
controls (Po0.001). Serum IL-17A
levels were significantly higher in
patients with active ocular disease
(29.8±18.2) compared with those of
patients with inactive ocular disease
(11.3±2.9) and healthy controls
(P¼0.003). Serum levels of IL-17A in
BD patients with active stages of oral
ulcers (29.4±10.1 vs. 15.1±11.4)
(Po0.001), genital ulcers (38.3±15.1
vs. 17.4±10.1) (Po0.001), and articu-
lar symptoms (34.9±17.9 vs.
17.9±10.5) (P¼ 0.002) were also
significantly higher than patients with
inactive stages of these symptoms.
Significant differences were also
observed in patients with active papu-
lopustular lesions (n:2) and erythema
nodosum (n:1) compared with those of
patients with inactive stages of these
symptoms (48.4±26.0 vs. 18.8±10.8;
39.9±17.9 vs. 19.9±12.9 pgml1, res-
pectively). Because of the limited
numbers of active patients, statistical
analysis was not applied. Differently
from the previously published data
(Hamzaoui et al., 2002; Chi et al.,
2008), our results showed that IL-17A
has an important role in acute attacks of
not only eye disease but also oral
ulcers, genital ulcers, and articular
symptoms. Serum IL-17A levels of BD
patients with inactive stage were not
different from healthy controls. This
result can be explained by the fact that
IL-17A is active only in acute inflam-
matory attacks of the disease.
Compared with healthy controls, a
significant increase was observed in the
number of IL-17A-producing cells
obtained from BD patients after stimu-
lation with S. sangius (P¼0.003),
E. coli (Po0.001), and phytohemaglu-
tinin (P¼ 0.008) in enzyme-linked im-
munosorbent spot method (Table 1).
We also stimulated PBMC of BD
patients and healthy controls with
60 kDa heat-shock protein to evaluate
IL-17A production. However, we did
not observe any IL-17A response in
both groups. We evaluated the re-
sponse of IFN-g, which was reported
to inhibit Th17 differentiation. Interest-
ingly, unlike IL-17A, both PBMC of BD
patients and healthy controls produced
IFN-g after stimulation with 60 kDa
heat-shock protein (data not presented).
To our knowledge, enzyme-linked im-
munosorbent spot assay is previously
unreported to detect IL-17A cytokine
production by PBMC for BD and
control groups in the literature. Our
enzyme-linked immunosorbent spot
findings confirm the ELISA results, and
the IL-17A responses of BD patients
are higher than healthy controls. Our
results suggest that S. sangius and
E. coli cause a higher response; but this
is not specific to BD patients (Kibaroglu
et al., 2004; Shibata et al., 2007). In the
literature, we have not found any
knowledge about the effects of heat-
shock protein on IL-17 production.
Our results suggest that heat-shock
protein might affect Th1 rather than
Th17-type immune response.
Although, an increase in the percen-
tage of IL-17A(þ ) lymphocytes,
CD4(þ ) IL-17A(þ ), and CD4() IL-
17A(þ ) T cells after S. sangius stimula-
tion of PBMC isolated from BD patients
was obtained, the differences were not
statistically significant. However, flow
cytometry data showed a significant
increase in the percentage of IL-17A(þ )
lymphocytes, CD4(þ ) IL-17A(þ ), and
CD4() IL-17A(þ ) T cells in BD
patients after stimulation with E. coli
and phytohemaglutinin (Table 2). Our
results, in general, are consistent with
those observed by Chi et al. (2008) and
emphasized the increased number of
IL-17A-producing cells in BD patients.
Our intracellular cytokine staining data
indicate that an important part of the IL-
17A-producing cells were CD4 () in
BD patients (Table 2); unfortunately, we
could not further analyze these CD4()
IL-17A-producing cells, which might be
gamma/delta T cells, CD8(þ ) lympho-
Table 1. Number of IL-17A-producing peripheral blood mononuclear cells
isolated from Behc¸et’s disease patients and healthy controls after
stimulation with S. sangius, E. coli, and phytohemaglutinin (PHA)1
Study group
stimulus
Patients with Behc¸et’s
disease (n: 33)
Healthy
controls (n: 25) P-value
S. sangius 157±72.3 87±68.0 0.003
E. coli 173±55.1 98±68.5 o0.001
PHA 188±42.1 132±74.0 0.008
1200,000 mononuclear cells were added to the wells and the final number of IL-17A-producing cells
were given after subtracting the number of unstimulated wells from stimulated wells.
Table 2. The proportion of IL-17A(+), CD4(+) IL-17A(+), and CD4()
IL-17A(+) T cells in Behc¸et’s disease patients with active organ
involvement and healthy controls after stimulation with S. sangius, E. coli,
and phytohemaglutinin (PHA)
Patients with Behc¸et’s disease (%) (n: 9) Healthy controls (%) (n: 9)
S. sangius E. coli PHA S. sangius E. coli PHA
IL-17A(+)
lymphocytes
2.14±2.57 4.01±2.88* 4.61±2.72** 1.04±0.38 1.37±0.31 2.81±0.44
CD4(+) IL-17A(+)
T cells
0.25±0.35 1.04±0.77w 0.73±0.43ww 0.16±0.12 0.16±0.08 0.17±0.16
CD4(-) IL-17A(+)
T cells
0.45±0.52 1.46±1.16z 1.05±0.87zz 0.16±0.12 0.16±0.08 0.17±0.16
A significant increase in the percentage of IL-17A(+) lymphocytes, CD4(+) IL-17A(+), and CD4() IL-
17A(+) T cells in Behc¸et’s disease patients after stimulation with E. coli (*P=0.004; wP=0.002;
zP=0.001, respectively) and PHA (**P=0.006; wwP=0.001; zzP=0.001, respectively) was observed.
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cytes, or natural killer cells (Roark
et al., 2008).
Taken together, our results indicate
that Th17 and IL-17 pathway are active
in BD patients, and has an important
role particularly in acute attacks of the
disease. Neutrophil activity is increased
in BD, and the affected organs show a
significant neutrophile infiltration.
Our data suggest that this result might
be caused by increased IL-17A res-
ponse in patients with BD. Treatment
modalities attempting to evaluate novel
approaches to eliminate the overactiv-
ity of IL-17A and/or IL-23–Th17 path-
way may clarify the biological
importance of IL-17A and Th17 cells
in patients with BD.
Our study, however, had also some
limitations. It is wise to keep in mind
that the increased IL-17A serum levels
is not clinical sign-specific and even
not disease-specific; it indicates inflam-
mation during the acute phases of
the disease with involvement of neu-
trophils. It might have been of more
scientific value to investigate longitudi-
nal evaluation of IL-17A and other
cytokine (IL-6, IL-8, tumor necrosis
factor-a, and so on) serum levels in a
group of patients with active and
inactive periods of the disease.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This study was supported by the Akdeniz University
Scientific Research Projects Unit, and has been
presented in the 39th Annual European Society for
Dermatological Research Meeting, Budapest-
Hungary, 9–12 September 2009.
Nurten Sayin Ekinci1, Erkan Alpsoy2,
Ayse Akman Karakas2, Senem
Buyukkara Yilmaz2 and
Olcay Yegin1
1Department of Pediatric Immunology,
Akdeniz University School of Medicine,
Antalya, Turkey and 2Department of
Dermatology and Venerology, Akdeniz
University School of Medicine, Antalya, Turkey
E-mail: ealpsoy@akdeniz.edu.tr
REFERENCES
Akman A, Kacaroglu H, Donmez L et al. (2007)
Relationship between periodontal findings
and Behcet’s disease: a controlled study.
J Clin Periodontol 34:485–91
Akman A, Sallakci N, Coskun M et al. (2006)
TNF-alpha gene 1031 T/C polymorphism
in Turkish patients with Behcet’s disease.
Br J Dermatol 155:350–6
Alpsoy E, Donmez L, Onder M et al. (2007)
Clinical features and natural course of
Behcet’s disease in 661 cases: a multicentre
study. Br J Dermatol 157:901–6
Chi W, Zhu X, Yang P et al. (2008) Upregulated IL-
23 and IL-17 in Behc¸et patients with active
uveitis. Invest Ophthalmol Vis Sci 49:
3058–64
Fossiez F, Djossou O, Chomarat P et al. (1996)
T cell IL-17 induces stromal cells to produce
proinflamatory and hematopoietic cytokines.
J Exp Med 183:2593–603
Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR
(2007) Autoimmune inflammation from the
Th17 perspective. Autoimmun Rev 6:169–75
Hamzaoui K, Hamzaoui A, Guemira F et al.
(2002) Cytokine profile in Behc¸et’s disease
patients: relationship with disease activity.
J Rheumatol 31:205–10
International Study Group for Behc¸et’s Disease
(1990) Criteria for diagnosis of Behc¸et’s
disease. Lancet 335:1078–80
Kawakami T, Ohashi S, Kawa Y et al. (2004)
Elevated serum granulocyte colony-stimulat-
ing factor levels in patients with active phase
of sweet syndrome and patients with active
behcet disease: implication in neutrophil
apoptosis dysfunction. Arch Dermatol
140:570–4
Kibaroglu A, Eksioglu-Demiralp E, Akoglu T et al.
(2004) T and NK cell subset changes with
microbial extracts and human HSP60-de-
rived peptides in Behc¸et’s disease. Clin Exp
Rheumatol 22(4 Suppl 34):S59–63
Roark CL, Simonian PL, Fontenot AP et al. (2008)
Gammadelta T cells: an important source of
IL-17. Curr Opin Immunol 20:353–7
Shibata K, Yamada H, Hara H et al. (2007)
Resident Vdelta1+ gammadelta T cells con-
trol early infiltration of neutrophils after
Escherichia coli infection via IL-17 produc-
tion. J Immunol 178:4466–72
Human b Defensin-2: Too Good to Be Dismissed in Atopic
Dermatitis
Journal of Investigative Dermatology (2010) 130, 2138–2139; doi:10.1038/jid.2010.101; published online 29 April 2010
TO THE EDITOR
I read with interest the study by Harder
et al. (2010), as they confirmed the
previous finding that the human b
defensin-2 (hBD-2) level in atopic
dermatitis (AD) lesions is lower than
that in psoriatic lesions, but higher than
healthy skin (Ong et al., 2002).
Based on the observation that psor-
iasis patients rarely suffer from skin
infections (Henseler and Christophers,
1995), Harder et al. (1997) made their
seminal discovery of hBD-2 in psoriatic
lesions. This antimicrobial peptide
(AMP) has since been proven to be the
strongest and most psoriasis-specific
protein (de Jongh et al., 2005; Gam-
bichler et al., 2008). In addition, it has
been shown to have immunomodula-
tory effects on innate and adaptive
immunity (Yang et al., 1999). Although
hBD-2 has weak direct antimicrobial
activity against Staphylococcus aureus
(Harder et al., 1997), the amount of
hBD-2 present in psoriatic lesions sig-
nificantly exceeds the amount required
for both antimicrobial effects (2.5–25mM)
and immunomodulation (2.5–250nM)
(Jansen et al., 2009). On the other hand,
the amount of hBD-2 present in AD
lesions, although higher than that in
healthy skin, has not been proven to
exceed these ranges. Furthermore, corre-
lation between hBD-2 level and clinical
infection in AD has not been studied.
However, the findings of Harder et al.
Abbreviations: AD, atopic dermatitis; AMP, antimicrobial peptide; CCR6, chemokine receptor; hBD-2,
human b defensin-2
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